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Abstract
Summary Patients with diabetes have an increased risk of fractures. In this study, subtrochanteric and femoral shaft fractures
were increased in patients with type 1 diabetes compared with the general population. In the light of this, more evidence points
towards an association between diabetes and atypical femoral fractures.
Introduction Patients with diabetes have an increased risk of femoral fractures, but little is known about the risk of atypical
femoral fractures (AFFs). The aim of this study was to identify the risk of subtrochanteric and femoral shaft (ST/FS) fractures and
estimate the risk of AFFs in patients with type 1 (T1D) and type 2 diabetes (T2D).
Methods From the nationwide Danish National Patient Register, we identified patients with T1D (n = 19,896), T2D (n =
312,188), and sex- and aged-matched controls without diabetes (n = 996,252) from the general population and all ST/FS fractures
(n = 7509). Data were analyzed using a Cox proportional-hazards model and the incidence rate and rate ratio of ST/FS fractures
were estimated.
Results The incidence rate of ST/FS fractures in T1D was 52.14 events per 100,000 person years and 73.21 per 100,000 person
years in T2D. T1D was associated with an increased risk of ST/FS (HR 2.07 (95% CI 1.68–2.56)), whereas T2D was not (HR
0.99 (95% CI 0.94–1.10)). Previous ST/FS fractures were associated with an increased risk of subsequent ST/FS fractures (HR
6.95 (95% CI 6.00–8.05)) and the use of bisphosphonates with an increased risk of ST/FS fractures (HR 1.72 (95% CI 1.54–
1.91)).
Conclusion Patients with T1D have a higher risk of ST/FS fractures compared with sex- and age-matched controls. Since a
proportion of ST/FS fractures are classified as AFFs, this could point towards the fact that AFFs also are increased in patients with
T1D, but not T2D.
Keywords Atypical femoral fractures . Diabetes type 1 . Diabetes type 2 . Femoral shaft fracture . Fractures . Subtrochanteric
fracture
Introduction
Patients with type 1 diabetes (T1D) and type 2 diabetes (T2D)
are associated with an increased risk of falls and fragility frac-
tures compared with the general population [15, 31, 34, 38]. In
a recent meta-analysis, patients with T1D had a 3.16-fold in-
crease in the risk of any fracture (95% confidence interval (CI)
1.51–6.63), whereas the fracture risk only increased by 19% in
patients with T2D (1.19 (95% CI 1.11–1.27)) [38, 44]. In an
effort to prevent fractures, antiresorptive medication has com-
monly been administrated, e.g., bisphosphonates (BP) and
denosumab. This treatment has significantly reduced the num-
ber of fractures by increasing the bone mineral density (BMD)
and improving bone microstructure [18]. However, the long-
term use of this medication has been associated with a higher
incidence of atypical femoral fractures (AFFs) [2, 5, 43]. In
general, AFFs are rare, but important to identify, because they
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are associated with a prolonged bone healing, increased risk of
complications, and long-term treatment regimens [1, 23, 24,
27]. AFFs have distinctive characteristics that distinguish
them from more commonly encountered femoral fractures.
The American Society for Bone and Mineral Research
(ASBMR) task force has defined AFFs by their anatomical
localization in the femur, the trauma mechanism, and the ra-
diographic features [40]. To satisfy the definition of AFFs, the
fracturemust be located along-side the femoral diaphysis from
just distal to the lesser trochanter to just proximal to the
supracondylar flare. The radiographic features and the trauma
mechanism distinguish AFFs from ordinary osteoporotic fem-
oral fractures [22]. According to the ASBMR task force, sev-
eral risk factors such as BPs, glucocorticoids, diabetes, and
older age increase the risk of AFFs. Both diabetes and BPs
have been associated with inducing a low bone turnover
which increases the risk of multiple micro-fractures with the
potential of leading to complete fractures over time [2, 5, 43].
A recent meta-analysis concluded that low bone turnover ap-
pears to be a common finding in diabetes [14]. AFFs also
occur in the absence of BPs and other antiresorptive agents,
suggesting that the low bone turnover, like that observed in
patients with T1D and T2D, could be an independent risk
factor for AFFs. However, contradictive studies on diabetes
and AFFs exist, and few cohort studies of patients with dia-
betes have been investigated.
Establishing the effect of specific risk factors of AFFs is
challenging due to the low incidence and the diagnostic
criteria from the ASBMR. However, gaining knowledge of
the potential risk and identifying specific risk factors of
AFFs could guide the choice of medication or initiate a closer
monitoring of people at higher risk of AFFs. Therefore, the
primary aim of this study was to approximate the risk of AFFs
by measuring the proportion of subtrochanteric and femoral
shaft (ST/FS) fractures in patients with diabetes compared
with a matched control group. A secondary aim was to iden-




Since 1968, the Danish Civil Registry System has assigned a
unique 10-digit civil registry number (the CPR number) to all
Danish residents at birth or immigration. In all Danish regis-
tries, patients are identified by their CPR number [11]. This
enabled us to link national data on hospital diagnoses from the
Danish National Patient Registry (DNPR) to the prescribed
medication from the register of Medicinal Products Statistics
of the Danish Medicines Agency to identify all patients with
diabetes residing in Denmark. The DNPR tracks every
hospital admission in Denmark since 1977, recording dates
of admission and discharge. The registry covers 99.4% of all
discharge records fromDanish hospitals. It covers all inpatient
contacts, outpatient visits to the hospital, and outpatient visits
to clinics and emergency rooms [3]. Physicians use the Danish
version of the International Classification of Diseases 8th re-
vision (ICD-8) (1977–1993) and 10th revision (ICD-10)
(1994 onward) as part of the National Health Service
Classification System (SKS) to code diagnoses. SKS keeps
track of diagnoses, symptoms, health problems, and other
causes of patient-associated contacts with the health services.
Medications were extracted from the Medicinal Products
Statistics of the Danish Medicines Agency, which is a nation-
wide register on all prescription drugs sold in Danish pharma-
cies after the year of 1996 using the Anatomical
Therapeutically Chemical (ATC) classification system [46].
In Denmark, diagnostics and care of T2D is handled by
GPs, whereas endocrinologists see patients with T1D and
poorly regulated T2D regularly.
The study cohort
This investigation was carried out using a retrospective cohort
design of diabetics older than 18 years of age between the first
of January 1996 until the 31st of December 2017 and their
age- and sex-matched controls. Figure 1 shows the design and
flow of inclusion. The cohort was divided into three groups:
patients with T1D, patients with T2D, and age- and sex-
matched control subjects representing the general population.
Patients with T1D and T2D were identified via the ICD-10
codes and SKS system by their discharge diagnosis and by the
ATC classification system. T1D (n = 19,896) was defined as
the occurrence of at least one ICD-10 diagnosis code for T1D
(ICD-10 code DE10) and at least one ATC code for insulins
and analogs (ATC code A10A) and no ATC code for blood
glucose-lowering drugs, excl. insulins (ATC code A10B).
T2D (n = 312,188) was defined as subjects with at least one
ATC codeA10B and no ICD-10 code DE10. The controls (n =
996,252) were defined as non-diabetics from the general pop-
ulation matched by age and sex (3:1) with the total population
of patients with diabetes. Subgroup analyses were made for
patients with type 1 and type 2 diabetes and matched by age
and sex (1:1) with a separate control group (Table 2).
Endpoint and exposure
The primary endpoint was ICD-10-coded ST/FS fractures in
patients with diabetes compared with age- and sex-matched
controls. ST fractures (ICD-10 code DS72.2) and FS fractures
(ICD-10 code DS72.3) were identified in all the three groups.
A secondary endpoint was to identify risk factors of ST/FS
fractures among patients with diabetes. Exposure was time to
event of an ST/FS fracture from the diabetes diagnosis or a
448 Osteoporos Int (2020) 31:447–455
corresponding dummy date for the age- and sex-matched
controls.
Statistical analyses
Descriptive statistics were presented with a mean and standard
deviation (SD) or percentage of people. t tests, chi-square
tests, and Mann–Whitney U tests were used to present statis-
tical differences in person characteristics. In a subgroup anal-
ysis matched by age and sex, the incidence rate (IR) and the
incidence rate ratio (IRR) of ST/FS fractures were estimated
from the time of diagnosis or of a corresponding dummy date
for controls to the first event of ST/FS fracture for T1D or T2D
patients. To exclude the same event twice, a dicatom variable
was created by measuring the proportion of ST/FS fractures
before and after the diagnosis. A Cox regression model was
constructed to analyze the association of T1D and T2D with
ST/FS fractures (Table 3). Covariates in the model included
age, sex, previous ST/FS fractures, previous alcohol abuse
including problems with alcohol use (ICD-10 code DF10)
and psychiatric disorder and behavioral disorder from alcohol
use (SKS code DZ721), previous knee and hip arthroplasties
(SKS codes KNGG and KNFG), previous osteoporosis and
fractures related to osteoporosis (ICD-10 codes M80-M82),
and previous use of per oral and systemic glucocorticoids
(ATC code H02AB) and bisphosphonates (ATC code
M05BA). The analyses were conducted in SAS 9.4. The sig-
nificance level was set at a p value of less than 0.05 for two-
sided testing.
Results
Table 1 shows the person characteristics of patients with T1D
(n = 19,896), T2D (n = 312,188), and controls (n = 996,252) at
the time of diagnosis. Themean age was lower in patients with
T1D (36 years) compared with that in T2D patients (60 years).
A higher proportion of men than women was seen in each
group: T1D (60.1%), T2D (52.5%), and controls (52.9%).
Previous use of BPs and glucocorticoids was higher in pa-
tients with T2D (2.0% and 22.2%, respectively) compared
with T1D (1.1% and 11.9%, respectively). Also, a previous
diagnosis of osteoporosis was more frequent in T2D (2.3%)
than in T1D (1.4%). On the contrary, patients with T1D
(4.4%) showed a higher proportion of previous diagnoses of
alcohol abuse than T2D (2.2%).
Table 2 is an adjusted subgroup analysis showing the IR of
ST/FS fractures in T1D and matched controls and T2D and
matched controls. This showed an IR of 52.14 events per
100,000 person years for an ST/FS fracture in T1D patients
compared with 37.7 events for the control group, which yielded
an IRT1D/IRControl of 1.38. Patients with T2D showed an IR of
73.21 events and similar values were shown for the control
group (IR of 81.0 events) yielding an IRT2D/IRControl of 0.90.
Table 3 and Fig. 2 show the results from the Cox regression
analysis and the incidence plots, respectively. T1D was asso-
ciated with a higher risk of ST/FS fractures (HR of 2.07 (95%
CI 1.68–2.56)) whereas T2Dwas not (HR 0.99 (95%CI 0.94–
1.10)). Women were more likely to have ST/FS fractures (HR
1.48 (95% CI 1.41–1.55)) as compared with men. A previous
ST/FS fracture was associated with a higher risk of an
Subjects with ICD10 DS722 code and DS723 code 
Subtrochanteric and femoral sha fracture
All Danish adult cizens between 1996 –
2017
90,510
Subjects with ICD-10 DE10 code
314,168
Subjects with ATC A10B
19,896
Subjects with ATC A10A and not A10B
Type 1 diabetes
996,252
Subjects without diabetes 
Controls
312,188 
Subjects with no ICD-10 DE10 code
Type 2 diabetes
91 cases 1,535 cases 5,883 cases
Fig. 1 Number of people in the study. From the Danish National Patient
Register (DNPR), 19,896 people were identified having type 1 diabetes
and 312,188 people type 2 diabetes. These were matched with 996,252
controls from the general population without diabetes by age and sex
(3:1). All cases of subtrochanteric and femoral shaft fractures were
identified in each group. Classification of Diseases 10 (ICD-10) system
and the Anatomical Therapeutical Chemical (ATC) classification system:
femoral shaft fractures (ICD-10 code DS72.3), subtrochanteric fractures
(ICD-10 code DS72.2), type 1 diabetes (ICD-10 code DE10). ATC code
for insulins and analogs (ATC code A10A). ATC code for blood glucose-
lowering drugs, excl. insulins (ATC code A10B)
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additional ST/FS fracture (HR 6.95 (95% CI 6.00–8.05)). An
increased risk of ST/FS fractures was seen with advancing
age, especially in the age span between 40 and 90 years of
age. People with osteoporosis and fractures related to osteo-
porosis were more likely to suffer from an ST/FS fracture (HR
1.30 (95% CI 1.16–1.46)). Previous use of BPs showed an
increased risk of ST/FS fractures (HR 1.72 (95% CI 1.54–
1.91)), but not the previous use of glucocorticoids (HR 1.05
(95% CI 0.99–1.12)). Previous alcohol abuse showed a sig-
nificant increase in the risk of ST/FS fractures (HR 4.00 (95%
CI 3.51–4.55)). Finally, few events of arthroplasties were ob-
served, and no significant increase of ST/FS fractures was
seen (HR 1.83 (95% CI 0.59–5.68)).
Discussion
In this population-based cohort study, we showed that
patients with T1D have an increased risk of ST/FS
fractures compared with matched controls. Age, previous
ST/FS fractures, osteoporosis, BPs, and alcohol abuse
were associated with an increased risk of ST/FS fractures.
The IR of ST/FS fractures for T1D showed comparable
values to studies on patients without diabetes treated with
BPs [10, 28, 30, 35].
Diabetes, bone turnover, and AFFs
Diabetes is associated with a low bone turnover and a
recent meta-analysis concluded that it appears to be a
common finding in diabetes [14, 38]. The low bone turn-
over in diabetes is believed to be caused by osteocyte
dysfunction and increased sclerostin levels resulting in
bone micro-cracks [43]. Other studies have shown an in-
crease in mineralization and non-enzymatic collagen
cross-links and have found lower total trabecular BMD
values [9, 33, 39]. This histological pattern in patients
with diabetes is in part similar to that reported in patients
Table 1 Person characteristics of patients with type 1 diabetes, type 2 diabetes, and controls
Variable exposure T1D T2D Controls p
Number of people 19,896 312,188 996,252
Age (SD) 36 (24) 60 (16) 59 (17) –
Age interval
< 30 years 9440 (47.4) 15,235 (4.9) 74,025 (7.4) –
30–40 years 2197 (11.0) 20,131 (6.4) 66,984 (6.7) –
40–50 years 2006 (10.1) 35,246 (11.3) 111,756 (11.2) –
50–60 years 2047 (10.3) 67,721 (21.7) 209,304 (21.0) –
60–70 years 1923 (9.7) 82,545 (26.4) 253,404 (25.4) –
70–80 years 1506 (7.6) 61,680 (19.8) 189,558 (19.0) –
80–90 years 689 (3.5) 26,036 (8.3) 80,175 (8.0) –
> 90 years 88 (0.4) 3594 (1.2) 11,046 (1.1) –
Sex
Women (%) 7943 (39.9) 148,381 (47.5) 468,972 (47.1) –
Men (%) 11,953 (60.1) 163,807 (52.5) 527,280 (52.9) –
Fractures
ST of femur (%) 57 (62.6) 920 (59.9) 3585 (60.9) 0.000
SF of femur (%) 34 (37.4) 615 (40.1) 2298 (39.1) 0.000
ST/FS fractures (%) 91 (0.46) 1535 (0.49) 5883 (0.59) 0.000
Previous ST/FS fracture (%) 57 (0.3) 774 (0.2) 2507 (0.3) 0.889
Previous arthroplasties* (%) 5 (0.0) 49 (0.0) 125 (0.0) 0.110
Previous use of medicine
Peroral or systemic glucocorticoids (%) 2364 (11.9) 69,252 (22.2) 169,450 (17.0) 0.000
Bisphosphonates (%) 219 (1.1) 6349 (2.0) 27,429 (2.8) 0.000
Others
Previous alcohol abuse (%) 840 (4.2) 6982 (2.2) 17,574 (1.8) 0.000
Previous osteoporosis (%) 270 (1.4) 7105 (2.3) 28,962 (2.9) 0.000
ST/FS subtrochanteric and femoral shaft fractures
* Arthroplasties in the knee or hip
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on long-term treatment with BPs who sustain AFFs [4].
However, contradictive data exists on whether diabetes
also affects the risk of AFFs. In population-based studies,
only a few studies have shown that diabetes is associated
with an increased risk of AFFs, whereas several larger
studies suggest that patients with diabetes are at lower
risk of AFFs [10, 12, 25, 29, 36]. A recent study showed
an increased risk of low-energy ST/FS fractures in pa-
tients with diabetes after adjustment for BMD, age, and
BPs (HR of 3.25 (95% CI 1.55–6.82)) [29]. Another ret-
rospective case-control study of patients with low-energy
ST/FS fractures included radiological features and found a
2-fold higher prevalence of diabetes in AFF cases com-
pared with femoral fracture cases [12]. Other studies have
reported a lower prevalence of diabetes in AFF cases
compared with the overall population [10, 25, 36].
However, given the potential relationship of diabetes to
bone turnover and in the light of the results in this study,
more evidence points towards an association between di-
abetes and AFFs. In this study, patients with T1D, but not
T2D, were significantly associated with an increased ST/
FS fracture risk. The reason for this discrepancy between
T1D and T2D may be that T1D is often diagnosed in a
younger age leading to a more profound change in bone
composition over time. Furthermore, patients with T2D
are often overweight in contrast to patients with T1D,
who are often of normal weight or even underweight.
The extra weight in patients with T2D perhaps manifests
especially around the hips as padding, possibly having a
hip protecting effect. On the contrary, a study on obese
women without diabetes showed no protecting effect re-
garding obesity and hip fractures [16]. Diabetes and bone
are complex and the discrepancy in ST/FS fractures thus
represents an interesting insight into bone biomechanical
competence in T1D and T2D, which requires further
study.
Risk factors
In this study, potential risk factors were identified and will be
discussed in the following.
People with osteoporosis and people treated with BPs were
independently associated with ST/FS fractures. This could
indicate that ST/FS fractures or AFFs are an extreme manifes-
tation of severe osteoporosis with decreased bone biomechan-
ical competence or represent a distinctive entity defined as
AFFs. In addition, commencement of BP treatment does not
necessarily occur in patients with severe osteoporosis alone,
although BPs would be indicated. Furthermore, the associa-
tion between ST/FS fractures and BPs matched other study
findings using similar methods. In previous studies, the long-
term use of BPs has shown IRs between 3.2 and 50 events per
100,000 person years for AFFs [40]. A comparable IR was
seen in this study of patients with T1D and the risk for ST/FS
fractures. In addition, the corresponding IRR was lower than
the adjusted Cox regression model, indicating multiple expo-
sures, such as BPs. Due to the risk of AFFs, physicians tend to
undertreat patients with diabetes with BPs for osteoporosis
compared with the general population [45]. In view of the
low IR, the benefits of treating osteoporosis in patients with
diabetes with BPs significantly outweigh the risk of ST/FS
fractures or of AFFs, and treatment should be considered sim-
ilar to the general population [19].
In this study, people with a previous ST/FS fracture showed
a 7-folded increase of an additional fracture. In general, pre-
vious non-accidental and low-energy non-AFFs increase the
risk of an additional fracture, and the same mechanism may
apply for ST/FS fractures [7, 42]. Moreover, the non-AFF
fractures could also increase the risk of AFFs, but more studies
are needed to explore this.
People with a previous alcohol abuse were highly associ-
ated with an increased risk of ST/FS fractures. A recent study
showed a 3-folded increase of fractures in patients with dia-
betes associated with an alcohol-related diagnosis [42]. There
are several mechanisms whereby alcohol might adversely af-
fect the fracture risk. Over time, alcohol decreases the bone
turnover due to malabsorption, malnutrition, and metabolic
effects from alcohol resulting in calcium deficits, which could
increase the risk of AFFs [17, 32]. Patients with diabetes,
especially T1D, are often malnourished and in deficit of vital
minerals and vitamins due to autonomic effects of the disease
[17]. The negative effects from extensive use of alcohol could
be more pronounced in patients with diabetes compared with
Table 2 Subgroup analyses. An estimate of the incidence rates per 100,000 person years and incidence rate ratios for a subtrochanteric or a femoral
shaft fracture in patients with type 1 diabetes or type 2 diabetes to a matched control group by age and sex 1:1
Group Fracture type IR per 100.000 person years: DM IR per 100.000 person years: controls IRR (95% CI)
T1D Subtrochanteric fracture 32.66 21.47 1.52 (1.02–2.27)
Femoral shaft fracture 19.48 16.23 1.20 (0.74–1.95)
T2D Subtrochanteric fracture 43.88 48.71 0.90 (0.83–0.98)
Femoral shaft fracture 29.33 32.28 0.91 (0.82–1.01)
IRRs in italics indicate statistically significant results: p < 0.05
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patients without diabetes. Therefore, alcohol should be con-
sidered a severe risk factor of ST/FS fractures among other
diseases.
Both increasing age and women were associated with ST/
FS fractures. In general, women have an increased risk of
fractures, including ST/FS fractures and AFFs, probably due
to the lack of estrogen following menopause [8, 13, 36]. On
average, patients who develop AFFs or ST/FS fractures are
younger (2–6 years) than those who develop non-AFFs [36].
Similar to femoral fractures, the risk of AFFs increases with
age, and BPs delay the risk of femoral fractures, but accelerate
the occurrence of AFFs.
Glucocorticoids are known to reduce bone turnover which
increases the risk of osteoporosis and fractures, but in this
study, they did not increase the risk of ST/FS fractures [].
Yet other studies have suggested a positive correlation be-
tween glucocorticoids and AFFs [6]. The variety of durations,
doses, and conditions for which glucocorticoids are used has
complicated the assessment of the relationship to AFFs. It is
probable that those on higher doses of glucocorticoids may
also be more likely to be using BPs. However, in this study
design, both exposures were excluded in the adjusted analysis.
Strengths
This study has a number of advantages for addressing the
association of diabetes to ST/FS fractures. It is a cohort study
which allows for population-based estimates of incidences,
risk assessments, and characterization of ST/FS fractures in
patients with diabetes. In addition, the control group repre-
sents the general population, which gives the opportunity to
estimate the absolute number of ST/FS fractures in the popu-
lation compared to, e.g., case-control studies which tend to use
a fracture control group. Furthermore, comprehensive adjust-
ments eliminated the confounding risk factors associated with
ST/FS fractures as previous fractures, arthroplasties, osteopo-
rosis, BPs, alcohol abuse, glucocorticoids, age, and sex.
Especially hip and knee arthroplasties did not increase the risk
Table 3 Results from the Cox regression analysis with events of subtrochanteric and femoral shaft fractures as outcome and diabetes, age, sex, fracture,
medicine, alcohol, and osteoporosis as exposure
HR 95% CI p
Type < 0.0001
T1D 2.07 1.68–2.56
T2D 0.99 0.94–1.10 0.7883
Controls 1 – –
Sex
Women 1.48 1.41–1.55 < 0.0001
Male 1 – –
Age interval/years
< 30 1 – –
30–40 1.01 0.67–1.52 0.9691
40–50 2.99 2.18–4.10 < 0.0001
50–60 4.67 3.48–6.27 < 0.0001
60–70 11.42 8.56–15.22 < 0.0001
70–80 28.97 21.76–38.57 < 0.0001
80–90 71.03 53.30–94.67 < 0.0001
> 90 125.43 92.23–170.54 < 0.0001
Fractures
Previous fractures (yes) 6.95 6.00–8.05 < 0.0001
Previous arthroplasties (yes) 1.83 0.59–5.68 0.2957
Previous use of medicine
Systemic or peroral glucocorticoids (yes) 1.05 0.99–1.12 0.0806
Bisphosphonates (yes) 1.72 1.54–1.91 < 0.0001
Others (previous)
Alcohol abuse (yes) 4.00 3.51–4.55 < 0.0001
Osteoporosis (yes) 1.30 1.16–1.46 < 0.0001
The model was adjusted for diabetes, age, sex, previous subtrochanteric and femoral shaft fractures, previous arthroplasties in the knee or hip, previous
systemic or peroral glucocorticoids, previous bisphosphonates, previous alcohol abuse, and previous osteoporosis. Hazard ratios (HR) in italics indicate
statistically significant results. CI, confidence interval
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of ST/FS fractures, but have been associated with an increased
risk of periprosthetic ST/FS fractures among BP users, which
in some studies account for 15% of the cases [22].
ICD-10 codes were used to identify ST/FS fractures. In
most studies restricted to ICD codes of ST/FS fractures, the
majority (75–95%) did not meet the ASBMR criteria and
would not qualify as AFFs [36]. Upon radiographic review,
most ST/FS fractures were, e.g., periprosthetic, pathologic
fractures, miscoded intertrochanteric fractures, osteoporotic
fractures, or ST/FS fractures that were not AFFs [20].
However, the validity of registrations in the DNPR is in gen-
eral very high, and especially the surgical diagnosis codes as
ST/FS and arthroplasties (95% validation or higher) [26, 37,
41]. Therefore, a proportion of the ST/FS fractures could be
considered AFFs. Moreover, analyzing the total number of
ST/FS fractures allows for inferences about the potential net
harm and provide an estimate of the upper boundary of harm
of all fractures located in this part of the femur in patients with
diabetes. An optimal setting could include the ASBMR
criteria, but access to medical journals or radiographic features
was not possible. The ASBMR criteria are considered to be of
high value in identifying AFFs. However, a recent study
found discrepancies between ASBMR criteria–based and
expert-based determinations on how to classify specific radio-
logical features in almost one-third of the cases [21]. The
ASBMR criteria are useful, but several features could be dif-
ficult to interpret when applying the radiological features.
Limitations
In this study, people with T1D have an increased risk of ST/FS
fractures compared with controls. However, some limitations
have to be considered. First, additional adjustment for other
antiresorptives and body mass index (BMI) was not added to
the analyses, due to the limited cases of ST/FS fractures and
the restricted access to patient records. Denosumab was intro-
duced in 2011 and the registered effect so far on AFFs is
limited. Regarding BMI and AFFs, limited data exits.
However, two studies showed no connection between BMI
and ST/FS fractures or verified radiological AFFs, whereas
another small study found that AFF patients had a higher
BMI than controls [, 10]. Second, approximately 70,000 peo-
ple were excluded in the study designwhen adding at least one
ATC code for insulins and analogs (ATC A10A) and no ATC
code for blood glucose-lowering drugs, excl. insulins (ATC
code A10B). However, the majority of this cohort are most
likely patients with T2D with a hospital diagnosis at the time
of admission. Therefore, these subjects could not have influ-
enced the T1D cohort. Third, ICD-10 codes were used to
identify ST/FS fractures as a proportion of AFFs. According
to newer guidelines, the ASBMR criteria should be applied.
However, identifying an increased risk of ST/FS fractures thus
represents an interesting insight into the complex mechanism
of bone biomechanicals and open up the possibility that the
risk of AFFs also could be increased, which requires further
study.
Conclusion
In conclusion, this study showed an increased risk of ST/FS
fractures in patients with T1D. Analyses of ST/FS fractures in
patients with diabetes provide valuable information about the
potential net harm and upper boundary of harm of all fractures
located in the ST/FS region. Moreover, using a cohort study
design allowed for extensive adjustments, not seen in similar
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Fig. 2 Incidents plot of hazard ratios from the Cox regression. Years from
diabetes diagnosis or a dummy date for controls to first incidence of
subtrochanteric and femoral shaft fracture. The model was adjusted for
age, sex, previous subtrochanteric and femoral shaft fractures, previous
arthroplasties in the knee or hip, previous use of systemic or peroral
glucocorticoids, previous bisphosphonates, previous alcohol abuse, and
previous osteoporosis. T1D compared to controls showed a p-value
< 0.0001 and T2D compared to controls showed a p-value of 0.7883
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studies, to eliminate confounding associated with ST/FS frac-
tures. Diabetes is associated with a low bone turnover which is
similar to that reported in patients on long-term treatment with
BPs who sustain AFFs. Hence, a similar etiology could exists
between diabetes and the development of AFFs. Furthermore,
a proportion of ST/FS fractures are AFFs. Therefore, the risk
of ST/FS fractures in this study could represent the risk of
AFFs in patients with T1D. In addition, several risk factors
were associated with ST/FS fractures and may represent risk
factors of AFFs. In an optimal setting, the ASBMR criteria for
AFFs could be added to reinforce the diagnosis.
AFFs are an extremely rare manifestation, but yet impor-
tant to be identified in order to reduce the severe consequences
associated with these fractures. Knowledge of the association
between diabetes, ST/FS fractures, AFFs, and potential risk
factors could prompt the physicians to initiate a closer clinical
monitoring of people at high risk with several risk factors to
prevent new cases of AFFs. Especially patients with diabetes
who have an increased risk of fragility fractures and falls could
benefit from this by reducing morbidity and increasing their
quality of life.
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